Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder

被引:53
|
作者
Ackerman, DL
Greenland, S
Bystritsky, A
机构
[1] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Inst Neuropsychiat, Anxiety Disorders Clin, Los Angeles, CA 90024 USA
关键词
D O I
10.1097/00004714-199806000-00002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Fluoxetine is effective in treating obsessive-compulsive disorder (OCD). Nonetheless, a substantial number of patients do not respond or have only partial improvement. Data generated by a multicenter, placebo-controlled, fixed-dose trial of fluoxetine were reanalyzed to identify characteristics of responders. Multiple regression methods were used to evaluate the relationship between therapeutic response and baseline measures such as; severity of-symptoms, type of symptoms (obsessions, compulsions, depression), course of illness, previous treatment, age of onset, and other demographic factors (age, race, and sex). Fluoxetine was more effective than placebo on all outcome measures. A 60-mg dosage was associated with a greater drop in Yale-Brown Obsessive-Compulsive Scale total score and a greater drop in Compulsion items than a 20-mg dosage. Response rates and overall improvement were greatest for patients with a history of remissions, with no previous drug treatment or with only prior behavior therapy, with more severe OCD (especially with greater interference and distress from obsessions), or with either low or high Hamilton Rating Scale for Depression scores. This study did not detect any associations between response and current age, age of OCD onset, gender, and race. None of the demographic or clinical factors evaluated was found to be related to improvement in the placebo group.
引用
收藏
页码:185 / 192
页数:8
相关论文
共 50 条
  • [31] Obsessive-compulsive disorder:: evaluation of clinical and biological circadian parameters during fluoxetine treatment
    Millet, B
    Touitou, Y
    Poirier, MF
    Bourdel, MC
    Amado, I
    Hantouche, EG
    Bogdan, A
    Olié, JP
    PSYCHOPHARMACOLOGY, 1999, 146 (03) : 268 - 274
  • [32] Obsessive-Compulsive Disorder in SchizophreniaClinical Characteristics and Treatment
    Michael Poyurovsky
    Abraham Weizman
    Ronit Weizman
    CNS Drugs, 2004, 18 : 989 - 1010
  • [33] FLUOXETINE - NO ASSOCIATION WITH SUICIDALITY IN OBSESSIVE-COMPULSIVE DISORDER
    BEASLEY, CM
    POTVIN, JH
    MASICA, DN
    WHEADON, DE
    DORNSEIF, BE
    GENDUSO, LA
    JOURNAL OF AFFECTIVE DISORDERS, 1992, 24 (01) : 1 - 10
  • [34] Predicting treatment response in obsessive-compulsive disorder
    Hurley, RA
    Saxena, S
    Rauch, SL
    Hoehn-Saric, R
    Taber, KH
    JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2002, 14 (03) : 249 - 253
  • [35] Sociodemographic and clinical characteristics in patients with obsessive-compulsive disorder with and without comorbid obsessive-compulsive personality disorder
    Uguz, Faruk
    Besiroglu, Luefullah
    Askin, Ruestem
    ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY, 2009, 10 (01): : 5 - 10
  • [36] A retrospective review of clinical characteristics and treatment response in body dysmorphic disorder versus obsessive-compulsive disorder
    Saxena, S
    Winograd, A
    Dunkin, JJ
    Maidment, K
    Rosen, R
    Vapnik, T
    Tarlow, G
    Bystritsky, A
    JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (01) : 67 - 72
  • [37] Obsessive-compulsive disorder Response
    Sheth, Sameer A.
    Eskandar, Emad N.
    JOURNAL OF NEUROSURGERY, 2013, 118 (03) : 490 - 490
  • [38] EFFICACY OF LONG-TERM FLUOXETINE TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
    FRENKEL, A
    ROSENTHAL, J
    NEZU, A
    WINSTON, A
    MOUNT SINAI JOURNAL OF MEDICINE, 1990, 57 (06): : 348 - 352
  • [39] Fluoxetine for the treatment of onychotillomania associated with obsessive-compulsive disorder: a case report
    Aljhani, Sumayah
    JOURNAL OF MEDICAL CASE REPORTS, 2022, 16 (01)
  • [40] OPEN FIXED DOSE TRIAL OF FLUOXETINE IN THE TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
    KIM, SW
    DYSKEN, MW
    DRUG DEVELOPMENT RESEARCH, 1990, 19 (03) : 315 - 319